Halozyme Therapeutics Inc (HALO)

[rod5247]

"Gilead’s drug was approved based on a 220-patient pivotal study that was stopped early because it clearly showed a benefit. At that point, patients in that study treated with idelalisib and rituximab lived an average of 10.7 months without seeing their tumors spread, compared to about 5.5 months for those on rituximab and a placebo. A second interim analysis showed that the results continued to hold up."